Mathai Mammen, SVP, Research & Early Clin Development at THERAVANCE INC (THRX), sold 25,000 shares at $26.15 ($643K) on 2012-08-13, disclosed to the SEC on 2012-08-15.
Scheduled sale ($643k) by SVP, Research & Early Clin Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.68 | 21,892 | $562K | 87.4% |
| 2 | $26.15 | 3,108 | $81K | 12.6% |
| Total | $25.74 avg | 25,000 | $643K | 100% |
| Filing → |
| THRX | SELL | 2013-08-01 | $256K | — | Filing → |
| THRX | SELL | 2013-05-02 | $236K | — | Filing → |
| THRX | SELL | 2013-02-22 | $155K | — | Filing → |